These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15118474)

  • 41. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
    Sutter FK; Simpson JM; Gillies MC
    Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Intraocular triamcinolone for diffuse diabetic macular edema].
    Degenring RF; Kreissig I; Jonas JB
    Ophthalmologe; 2004 Mar; 101(3):251-4. PubMed ID: 15007605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of postvitrectomy intravitreal triamcinolone therapy for diabetic macular edema.
    Costa JF; Sousa K; Marques JP; Marques M; Cachulo ML; Silva R; Gomes N; Figueira J
    Eur J Ophthalmol; 2016 Aug; 26(5):485-90. PubMed ID: 26951531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years.
    Islam MS; Vernon SA; Negi A
    Eye (Lond); 2007 Mar; 21(3):321-3. PubMed ID: 16543927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates.
    Khairallah M; Zeghidi H; Ladjimi A; Yahia SB; Attia S; Zaouali S; Messaoud R
    Retina; 2005; 25(7):835-9. PubMed ID: 16205560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal cortisone injection for refractory diffuse diabetic macular edema.
    Er H; Yilmaz H
    Ophthalmologica; 2005; 219(6):394-400. PubMed ID: 16286802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide.
    Detry-Morel M; Escarmelle A; Hermans I
    Bull Soc Belge Ophtalmol; 2004; (292):45-51. PubMed ID: 15253490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Malignant glaucoma as a complication of intravitreal triamcinolone acetonide.
    Heatley CJ; Lim KS; Siriwardena D; Barton K
    Acta Ophthalmol Scand; 2006 Oct; 84(5):712-3. PubMed ID: 16965510
    [No Abstract]   [Full Text] [Related]  

  • 49. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema.
    Lam DS; Chan CK; Mohamed S; Lai TY; Li KK; Li PS; Tsang CW; Chan WM; Shanmugam MP
    Br J Ophthalmol; 2007 Feb; 91(2):199-203. PubMed ID: 16973659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.
    Quiram PA; Gonzales CR; Schwartz SD
    Am J Ophthalmol; 2006 Mar; 141(3):580-2. PubMed ID: 16490518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complications of intravitreal steroid injections.
    Reichle ML
    Optometry; 2005 Aug; 76(8):450-60. PubMed ID: 16150412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anterior staphyloma following an intravitreal injection of triamcinolone for the treatment of diabetic macular edema.
    Detorakis ET; Papadaki T; Panteleontidis V; Pallikaris IG; Tsilimbaris MK
    Can J Ophthalmol; 2009 Aug; 44(4):473-4. PubMed ID: 19606183
    [No Abstract]   [Full Text] [Related]  

  • 53. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection.
    Yamamoto Y; Komatsu T; Koura Y; Nishino K; Fukushima A; Ueno H
    Can J Ophthalmol; 2008 Feb; 43(1):42-7. PubMed ID: 18204501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correspondence.
    Lorenzo-Carrero J
    Retina; 2009 Jun; 29(6):868-9; author reply 869. PubMed ID: 19516126
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review.
    Yilmaz T; Weaver CD; Gallagher MJ; Cordero-Coma M; Cervantes-Castaneda RA; Klisovic D; Lavaque AJ; Larson RJ
    Ophthalmology; 2009 May; 116(5):902-11; quiz 912-3. PubMed ID: 19410949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Incidence and risk factors of intraocular pressure elevation after triamcinolone acetonide administration for macular disorders].
    Ito T; Nozaki M; Ogura Y
    Nippon Ganka Gakkai Zasshi; 2006 May; 110(5):379-83. PubMed ID: 16764319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema.
    Avci R; Kaderli B; Akalp FD
    Clin Exp Ophthalmol; 2006; 34(1):27-32. PubMed ID: 16451255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Laser trabeculoplasty.
    Lau LI; Liu CJ; Chen SJ; Ko YC; Lee FL; Hsu WM
    Ophthalmology; 2007 Sep; 114(9):1790. PubMed ID: 17822985
    [No Abstract]   [Full Text] [Related]  

  • 60. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema.
    Batioğlu F; Ozmert E; Parmak N; Celik S
    Int Ophthalmol; 2007 Oct; 27(5):299-306. PubMed ID: 17453151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.